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Introduction and Aims:Women with chronic kidney disease (CKD) and chronic
hypertension (CHT) are at increased risk of superimposed pre-eclampsia (SPE) and
associated adverse pregnancy outcomes. Diagnosis of SPE using blood pressure and
proteinuria is of limited use because they may develop in women with CKD or CHT
without the condition. Inaccurate diagnosis may result in unnecessary iatrogenic
preterm delivery. Plasma and urinary aldosterone concentrations are elevated in
patients with CKD and CHT, but in established pre-clampsia (PE) are suppressed. The
aim of the study was to determine urinary aldosterone concentrations in women with
CKD and/or CHT with and without SPE compared with normotensive controls (NC)
and those with PE without CKD/CHT.
Methods: NC women (n=25), women with PE (n=22), CKD or CHT without SPE
(n=25) and with SPE (n=21) were recruited from two tertiary antenatal clinics (mean
±SD 38±3 weeks’). Urinary tetrahydroaldosterone was measured by gas
chromatography-mass spectrometry (GC-MS); creatinine was measured using a
standard clinical laboratory assay for normalisation.
Results: A Kruskal Wallis test indicated significant differences between groups
(P<0.0001). Aldosterone: creatinine ratios were significantly lower in both PE and SPE
compared to the NC and CKD/CHT women (median [IQR], PE: 6.45 [2.95, 14.37];
SPE: 10.82 [5.42, 16.44]; NC: 13.75 [9.07, 29.80]; CKD/CHT: 24.18 [16.29, 37.88] µg/
mmol creatinine; P<0.05 for all).
Conclusions:Women with SPE have lower urinary aldosterone than women with
CKD/CHT in keeping with women with PE without pre-existing disease, suggestive of
similar pathophysiology. Further exploration of the predictive value of low urinary
aldosterone for adverse pregnancy events in women with CKD and/or CHT and its role
in cases of diagnostic uncertainty is required.
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